BML-210(CAY10433)Novel HDAC inhibitor CAS# 537034-17-6 |
- CX-5461
Catalog No.:BCC3700
CAS No.:1138549-36-6
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Fludarabine Phosphate (Fludara)
Catalog No.:BCC3681
CAS No.:75607-67-9
- Bleomycin Sulfate
Catalog No.:BCC3694
CAS No.:9041-93-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 537034-17-6 | SDF | Download SDF |
| PubChem ID | 9543540 | Appearance | Powder |
| Formula | C20H25N3O2 | M.Wt | 339.43 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 30 mg/mL (88.38 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N'-(2-aminophenyl)-N-phenyloctanediamide | ||
| SMILES | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NC2=CC=CC=C2N | ||
| Standard InChIKey | RFLHBLWLFUFFDZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.
IC50 value: 5 μM[1]
Target: HDAC4
In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis[2]. BML-210 inhibits the growth of NB4 cells in dose- and time-dependent manner[3].
In vivo: References: | |||||
BML-210(CAY10433) Dilution Calculator
BML-210(CAY10433) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9461 mL | 14.7306 mL | 29.4612 mL | 58.9223 mL | 73.6529 mL |
| 5 mM | 0.5892 mL | 2.9461 mL | 5.8922 mL | 11.7845 mL | 14.7306 mL |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9461 mL | 5.8922 mL | 7.3653 mL |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL | 1.1784 mL | 1.4731 mL |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.5892 mL | 0.7365 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BML-210 (CAY10433) is a novel HDAC inhibitor with IC50 value of 87 μM [1].
Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from ε-N-acetyl lysines on histones, allowing the histones to wrap the DNA more tightly. DNA expression is regulated by de-acetylation and acetylation.
BML-210 (CAY10433) is a novel HDAC inhibitor. In FRDA lymphoid cell line (GM15850), BML-210 increased the level of FXN mRNA by 1.4-fold [1]. In the human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 induced G1 arrest and histone H4 acetylation, affected NF-κB and Sp1 binding to the p21 or the FasL promoters, and influenced expression of Sp1, NF-κB, p21 and FasL. BML-210 inhibited cell growth and induced apoptosis in a time- and dose-dependent way. BML-210 also induced K562 and HL-60 cell differentiation (up to 30%) to erythrocytes and granulocytes, respectively [2]. In HeLa cells, BML-210 (20 or 30 μM) increased the amount of cells in G0/G1 phase, caused sub-G1 accumulation, and induced apoptosis [3]. In human promyelocytic leukemia NB4 cells, BML-210 inhibited cell growth in a dose- and time-dependent way [4].
References:
[1]. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol, 2006, 2(10): 551-558.
[2]. Savickiene J, Borutinskaite VV, Treigyte G, et al. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol, 2006, 549(1-3): 9-18.
[3]. Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep, 2012, 39(12): 10179-10186.
[4]. Borutinskaitė V, Navakauskienė R. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci, 2015, 16(8): 18252-18269.
- 2-Acetyl-5-bromothiophene
Catalog No.:BCC8513
CAS No.:5370-25-2
- Mexiletine HCl
Catalog No.:BCC4677
CAS No.:5370-01-4
- beta-Amyrenonol methylthiomethyl ether
Catalog No.:BCN3354
CAS No.:
- N-Acetyl-m-toluidine
Catalog No.:BCC9083
CAS No.:537-92-8
- Soyasaponin Be Methyl Ester
Catalog No.:BCN5925
CAS No.:117210-13-6
- N-Acetyl-L-tyrosine
Catalog No.:BCC9082
CAS No.:537-55-3
- Pterostilbene
Catalog No.:BCN2539
CAS No.:537-42-8
- Chlorophorin
Catalog No.:BCN3288
CAS No.:537-41-7
- Convolvine
Catalog No.:BCN1904
CAS No.:537-30-4
- Isoporoidine
Catalog No.:BCN1890
CAS No.:537-28-0
- Tropacocaine
Catalog No.:BCN1934
CAS No.:537-26-8
- Diperodon HCl
Catalog No.:BCC3766
CAS No.:537-12-2
- Tubacin
Catalog No.:BCC2428
CAS No.:537049-40-4
- Carprofen
Catalog No.:BCC4645
CAS No.:53716-49-7
- Oxfendazole
Catalog No.:BCC4817
CAS No.:53716-50-0
- Bruceantinol
Catalog No.:BCN7616
CAS No.:53729-52-5
- Luteolin-7-O-glucoside
Catalog No.:BCN5388
CAS No.:5373-11-5
- Neorauflavane
Catalog No.:BCN4791
CAS No.:53734-74-0
- Neorauflavene
Catalog No.:BCN4848
CAS No.:53734-75-1
- Lyclaninol
Catalog No.:BCN5710
CAS No.:53755-76-3
- Lycernuic acid A
Catalog No.:BCN5711
CAS No.:53755-77-4
- UF 010
Catalog No.:BCC6478
CAS No.:537672-41-6
- CP-724714
Catalog No.:BCC1188
CAS No.:537705-08-1
- Ribostamycin Sulfate
Catalog No.:BCC4710
CAS No.:53797-35-6
